Showing 3 results for Farzadfar
Habibeh Taghavi Kojidi, Farshad Farzadfar, Niloofar Peykari, Bagher Larijani, Shadi Rahimzadeh, Ehsan Rezaei-Darzi, Sahar Saeedi Moghaddam,
Volume 15, Issue 2 (1-2016)
Abstract
Background: Thyroid cancer is the most common form of endocrine cancer. The age and gender-adjusted incidence of thyroid cancer has increased faster than that of any other malignancy in recent years, with the increased incidence seen in both genders, all ethnic backgrounds and all sizes of thyroid cancer. It appears that the rise in thyroid cancer incidence is not only due to medical surveillance and improved disease detection. In Iran, also scattered studies had been accomplished in different provinces and requirement to more attention and planning for thyroid cancer. Thyroid cancer’s control and prevention requires to the evidence–based strategies in different population groups based on national and provincial comprehensive studies on the prevalence and incidence. Thus we aimed to provide the comprehensive information about thyroid cancer prevalence and trend in national, provincial levels among Iranian population.
Methods: In this study we used some steps respectively to show how thyroid cancer prevalence changes in 1990 to 2010 between different provinces. We aggregate cancer registry data set by province, age categorized, gender and merge with other national covariates that were gathered in Iran. Then, linear regression model and logistic regression model were used to modeling and predicting for other provinces and years.
Results: Mean of thyroid cancer prevalence displayed that prevalence increased with increase in years especially more rapidly from 2002-2010 the prevalence rates were estimated to be (0.0-0.25) and (4.2-13.7) per 100000 in 1990 and 2010 respectively and increased in both females and males. Female to male ratio was 2.5. Highest prevalence thyroid cancer were in four provinces of Iran, Isfahan (mean rate 4.3 per 100000), Yazd (mean rate 4.1 per 100000), Tehran (mean rate 4 per 100000) and Qazvin (mean rate 3.1 per 100000) respectively.
Conclusion: Iran map displayed with increase in years, thyroid cancer prevalence become larger. Additional research on the risk factors for thyroid cancer is needed to explain the difference of thyroid cancer prevalence between provinces.
Sayed Mahmoud Sajjadi-Jazi, Farshad Sharifi, Mehdi Varmaghani, Hamidreza Aghaei Meybodi, Farshad Farzadfar, Vahid Haghpanah, Bagher Larijani,
Volume 19, Issue 3 (2-2020)
Abstract
Background: The aim of this study was to estimate the prevalence of clinical hyperthyroidism at the national and sub-national levels using the claims data.
Methods: National anti-thyroid medications (methimazole and propylthiouracil) sales data in 2014 were extracted from pharmaceutical sales data that were reported by Iran's Food and Drug Administration (FDA). By using prescriptions data of Social Security Insurance Organization (SSIO) and Medical Services Insurance Organization (MSIO) in 2014, age-sex-province proportions of drug consumptions and Defined Daily Dose (DDD) of anti-thyroid medications were calculated. Moreover, by systematic review and meta-analysis of published literatures in hyperthyroidism in Iran, the prescription rate of anti-thyroid medications was calculated. Finally by using the whole data, the prevalence of clinical hyperthyroidism was estimated in each age and sex groups in national and provincial levels.
Results: : The prevalence (95% confidence interval) of clinical hyperthyroidism in Iran in 2014 is 0.32% (0.21-0.51%); 0.44% (0.29-0.68%) in females and 0.2% (0.12-0.33%) in males. Among provinces the least prevalence rate of clinical hyperthyroidism is 0.24% (0.16-0.38%) which belongs to Sistan and Baluchistan, and the highest prevalence rate is 0.38% (0.24-0.6%) which belongs to Gilan.
Conclusion: The prevalence rate that reported by this study is compatible with other surveys which performed in the world and Iran. As a result using claims data is a good source to predict prevalence of chronic diseases that have specific drugs.
Sina Azadnajafabad, Sahar Saeedi Moghaddam, Esmaeil Mohammadi, Negar Rezaei, Nazila Rezaei, Shohreh Naderimagham, Rosa Haghshenas, Erfan Ghasemi, Yosef Farzi, Elham Abdolhamidi, Sahar Mohammadi Fateh, Hossein Zokaei, Ameneh Kazemi, Ozra Tabatabaei-Malazy, Farshad Farzadfar, Bagher Larijani,
Volume 20, Issue 1 (25th Anniversary of the Foundation, Special Issue 2021)
Abstract
Non-Communicable Diseases (NCDs) are the major cause of premature death and disability due to diseased globally, imposing a heavy burden on the health systems. Four main categories of NCDs are cardiovascular diseases, neoplasms, diabetes, and chronic respiratory diseases. Iran, the second greatest country in the Middle East Region, has been through an important transition period of communicable diseases toward NCDs in the last decades. One of the effective approaches to control NCDs is implementation of population-based studies and interventions, trying to reduce risk factors and incidence of NCDs through investigations in the populations. Endocrinology and Metabolism Research Institute (EMRI) and Non-Communicable Diseases Research Center (NCDRC) are the pioneers trying to study and control various NCDs during the last decades in Iran. In this review, we are going to inspect some of the major completed and ongoing projects of this research institute to highlight valuable efforts to reduce burden of NCDs in Iran, and make a successful example for national and regional public health policy makers and authorities.
